{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:28:26Z","timestamp":1790375306678,"version":"4.1.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["3347CO-108792"],"award-info":[{"award-number":["3347CO-108792"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12016-017-8617-4","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T19:46:15Z","timestamp":1498160775000},"page":"413-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Skin Manifestations of Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Thomas","family":"Greuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"Vavricka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"key":"8617_CR1","unstructured":"Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV (2016) Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 15(6):857\u2013863"},{"issue":"1","key":"8617_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(01)00002-4","volume":"31","author":"EV Loftus","year":"2002","unstructured":"Loftus EV, Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am 31(1):1\u201320","journal-title":"Gastroenterol Clin N Am"},{"key":"8617_CR3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28:573\u2013621","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"8617_CR4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116\u20131122","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"8617_CR5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129(3):827\u2013836","journal-title":"Gastroenterology"},{"key":"8617_CR6","unstructured":"Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, D\u00edaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn\u2019s disease and ulcerative colitis. Med Clin (Barc). 2005;125(8):297\u2013300."},{"issue":"3","key":"8617_CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","volume":"10","author":"E Ricart","year":"2004","unstructured":"Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR et al (2004) Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 10(3):207\u2013214","journal-title":"Inflamm Bowel Dis"},{"issue":"4 Pt 2","key":"8617_CR8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","volume":"77","author":"GB Rankin","year":"1979","unstructured":"Rankin GB, Watts HD, Melnyk CS, Kelley ML (1979) National Cooperative Crohn\u2019s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77(4 Pt 2):914\u2013920","journal-title":"Gastroenterology"},{"issue":"1","key":"8617_CR9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","volume":"31","author":"CG Su","year":"2002","unstructured":"Su CG, Judge TA, Lichtenstein GR (2002) Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin N Am 31(1):307\u2013327","journal-title":"Gastroenterol Clin N Am"},{"issue":"1","key":"8617_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"FT Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23(1):29\u201334","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"8617_CR11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","volume":"106","author":"SR Vavricka","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110\u2013119","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"8617_CR12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","volume":"15","author":"SR Vavricka","year":"2014","unstructured":"Vavricka SR, Scharl M, Gubler M, Rogler G (2014) Biologics for extraintestinal manifestations of IBD. Curr Drug Targets 15(11):1064\u20131073","journal-title":"Curr Drug Targets"},{"issue":"1","key":"8617_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3748\/wjg.v21.i1.21","volume":"21","author":"GE Tontini","year":"2015","unstructured":"Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H (2015) Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol 21(1):21\u201346","journal-title":"World J Gastroenterol"},{"issue":"3","key":"8617_CR14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55(3):426\u2013431","journal-title":"Gut"},{"issue":"2","key":"8617_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1373\/clinchem.2005.058560","volume":"52","author":"X Bossuyt","year":"2006","unstructured":"Bossuyt X (2006) Serologic markers in inflammatory bowel disease. Clin Chem 52(2):171\u2013181","journal-title":"Clin Chem"},{"issue":"9853","key":"8617_CR16","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ (2012) Crohn\u2019s disease. Lancet 380(9853):1590\u20131605","journal-title":"Lancet"},{"issue":"18","key":"8617_CR17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C (2011) Ulcerative colitis. N Engl J Med 365(18):1713\u20131725","journal-title":"N Engl J Med"},{"key":"8617_CR18","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11(6):649\u2013670"},{"issue":"1","key":"8617_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) Third European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 11(1):3\u201325","journal-title":"J Crohns Colitis."},{"key":"8617_CR20","doi-asserted-by":"crossref","first-page":"g6670","DOI":"10.1136\/bmj.g6670","volume":"349","author":"R Kalla","year":"2014","unstructured":"Kalla R, Ventham NT, Satsangi J, Arnott ID (2014) Crohn\u2019s disease. BMJ 349:g6670","journal-title":"BMJ"},{"issue":"6","key":"8617_CR21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2004.02.072","volume":"126","author":"BE Sands","year":"2004","unstructured":"Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126(6):1518\u20131532","journal-title":"Gastroenterology"},{"issue":"3","key":"8617_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","volume":"63","author":"C Charpentier","year":"2014","unstructured":"Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE et al (2014) Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 63(3):423\u2013432","journal-title":"Gut"},{"issue":"4","key":"8617_CR23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00042737-199704000-00007","volume":"9","author":"JE Lennard-Jones","year":"1997","unstructured":"Lennard-Jones JE, Shivananda S (1997) Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 9(4):353\u2013359","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9272","key":"8617_CR24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(00)05063-7","volume":"357","author":"J Hampe","year":"2001","unstructured":"Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al (2001) Association between insertion mutation in NOD2 gene and Crohn\u2019s disease in German and British populations. Lancet 357(9272):1925\u20131928","journal-title":"Lancet"},{"issue":"6837","key":"8617_CR25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","volume":"411","author":"JP Hugot","year":"2001","unstructured":"Hugot JP, Chamaillard M, Zouali H, Lesage S, C\u00e9zard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn\u2019s disease. Nature 411(6837):599\u2013603","journal-title":"Nature"},{"issue":"6837","key":"8617_CR26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","volume":"411","author":"Y Ogura","year":"2001","unstructured":"Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn\u2019s disease. Nature 411(6837):603\u2013606","journal-title":"Nature"},{"issue":"4","key":"8617_CR27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/auto.7.4.13074","volume":"7","author":"TS Stappenbeck","year":"2011","unstructured":"Stappenbeck TS, Rioux JD, Mizoguchi A, Saitoh T, Huett A, Darfeuille-Michaud A et al (2011) Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy 7(4):355\u2013374","journal-title":"Autophagy"},{"issue":"6","key":"8617_CR28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","volume":"146","author":"AD Kostic","year":"2014","unstructured":"Kostic AD, Xavier RJ, Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146(6):1489\u20131499","journal-title":"Gastroenterology"},{"issue":"3","key":"8617_CR29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2015.01.002","volume":"160","author":"JM Norman","year":"2015","unstructured":"Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC et al (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160(3):447\u2013460","journal-title":"Cell"},{"issue":"8","key":"8617_CR30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 369(8):711\u2013721","journal-title":"N Engl J Med"},{"issue":"5","key":"8617_CR31","first-page":"511","volume":"464","author":"C Langner","year":"2014","unstructured":"Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V et al (2014) The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch 464(5):511\u2013527","journal-title":"Virchows Arch"},{"issue":"10","key":"8617_CR32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.crohns.2013.06.001","volume":"7","author":"F Magro","year":"2013","unstructured":"Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ et al (2013) European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7(10):827\u2013851","journal-title":"J Crohns Colitis"},{"issue":"12","key":"8617_CR33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jclinpath-2013-201885","volume":"66","author":"RM Feakins","year":"2013","unstructured":"Feakins RM, Gastroenterology BS (2013) Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 66(12):1005\u20131026","journal-title":"J Clin Pathol"},{"issue":"8","key":"8617_CR34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00000478-199808000-00008","volume":"22","author":"CG Kleer","year":"1998","unstructured":"Kleer CG, Appelman HD (1998) Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 22(8):983\u2013989","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"8617_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/jcp.55.1.51","volume":"55","author":"SS Cross","year":"2002","unstructured":"Cross SS, Harrison RF (2002) Discriminant histological features in the diagnosis of chronic idiopathic inflammatory bowel disease: analysis of a large dataset by a novel data visualisation technique. J Clin Pathol 55(1):51\u201357","journal-title":"J Clin Pathol"},{"issue":"8","key":"8617_CR36","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982\u20131992","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"8617_CR37","first-page":"711","volume":"85","author":"U Mons\u00e9n","year":"1990","unstructured":"Mons\u00e9n U, Sorstad J, Hellers G, Johansson C (1990) Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 85(6):711\u2013716","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"8617_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1026629528233","volume":"44","author":"KM Das","year":"1999","unstructured":"Das KM (1999) Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 44(1):1\u201313","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"8617_CR39","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/S1590-8658(08)60534-4","volume":"40","author":"S Ardizzone","year":"2008","unstructured":"Ardizzone S, Puttini PS, Cassinotti A, Porro GB (2008) Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40(Suppl 2):S253\u2013S259","journal-title":"Dig Liver Dis"},{"issue":"4","key":"8617_CR40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00054725-200111000-00005","volume":"7","author":"FT Veloso","year":"2001","unstructured":"Veloso FT, Ferreira JT, Barros L, Almeida S (2001) Clinical outcome of Crohn\u2019s disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 7(4):306\u2013313","journal-title":"Inflamm Bowel Dis"},{"key":"8617_CR41","doi-asserted-by":"publisher","unstructured":"Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J et al (2016) Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation and anti-TNF treatment. J Pediatr Gastroenterol Nutr. doi: 10.1097\/MPG.0000000000001455","DOI":"10.1097\/MPG.0000000000001455"},{"issue":"2","key":"8617_CR42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MPG.0b013e3181ca4db4","volume":"51","author":"JL Dotson","year":"2010","unstructured":"Dotson JL, Hyams JS, Markowitz J, LeLeiko NS, Mack DR, Evans JS et al (2010) Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 51(2):140\u2013145","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"8617_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ibd.20604","volume":"15","author":"FA Jose","year":"2009","unstructured":"Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN et al (2009) Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 15(1):63\u201368","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"8617_CR44","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MPG.0b013e3181da1db8","volume":"51","author":"G Guariso","year":"2010","unstructured":"Guariso G, Gasparetto M, Vison\u00e0 Dalla Pozza L, D'Inc\u00e0 R, Zancan L, Sturniolo G et al (2010) Inflammatory bowel disease developing in paediatric and adult age. J Pediatr Gastroenterol Nutr 51(6):698\u2013707","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"8617_CR45","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1572-0241.2006.00552.x","volume":"101","author":"I Vind","year":"2006","unstructured":"Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M et al (2006) Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003\u20132005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 101(6):1274\u20131282","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"8617_CR46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ibd.21719","volume":"18","author":"SR Vavricka","year":"2012","unstructured":"Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C et al (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18(3):496\u2013505","journal-title":"Inflamm Bowel Dis"},{"key":"8617_CR47","doi-asserted-by":"crossref","unstructured":"Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V et al (2013) Diagnostic delay in Crohn\u2019s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 108(11):1744\u20131753","DOI":"10.1038\/ajg.2013.248"},{"issue":"5","key":"8617_CR48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"AJ Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB (1976) The extra-intestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55(5):401\u2013412","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"8617_CR49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(81)70130-0","volume":"5","author":"W Burgdorf","year":"1981","unstructured":"Burgdorf W (1981) Cutaneous manifestations of Crohn\u2019s disease. J Am Acad Dermatol 5(6):689\u2013695","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"8617_CR50","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1468-3083.2008.02741.x","volume":"22","author":"I Palamaras","year":"2008","unstructured":"Palamaras I, El-Jabbour J, Pietropaolo N, Thomson P, Mann S, Robles W et al (2008) Metastatic Crohn\u2019s disease: a review. J Eur Acad Dermatol Venereol 22(9):1033\u20131043","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"8617_CR51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.MIB.0000436959.62286.f9","volume":"20","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M (2014) Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 20(1):213\u2013227","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"8617_CR52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clindermatol.2007.10.018","volume":"26","author":"S Timani","year":"2008","unstructured":"Timani S, Mutasim DF (2008) Skin manifestations of inflammatory bowel disease. Clin Dermatol 26(3):265\u2013273","journal-title":"Clin Dermatol"},{"issue":"3","key":"8617_CR53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM et al (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 10(3):239\u2013254","journal-title":"J Crohns Colitis."},{"issue":"8","key":"8617_CR54","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA et al (2015) Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 21(8):1794\u20131800","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"8617_CR55","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ibd.20807","volume":"15","author":"I Y\u00fcksel","year":"2009","unstructured":"Y\u00fcksel I, Ba\u015far O, Ataseven H, Ertu\u011frul I, Arhan M, Ibi\u015f M et al (2009) Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 15(4):546\u2013550","journal-title":"Inflamm Bowel Dis"},{"key":"8617_CR56","first-page":"33","volume":"13","author":"W Huang","year":"1997","unstructured":"Huang W, McNeely MC (1997) Neutrophilic tissue reactions. Adv Dermatol 13:33\u201364","journal-title":"Adv Dermatol"},{"issue":"Suppl 1","key":"8617_CR57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000341950","volume":"86","author":"PL Lakatos","year":"2012","unstructured":"Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S (2012) Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 86(Suppl 1):28\u201335","journal-title":"Digestion"},{"issue":"3","key":"8617_CR58","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1542\/peds.2004-2281","volume":"116","author":"SS Galbraith","year":"2005","unstructured":"Galbraith SS, Drolet BA, Kugathasan S, Paller AS, Esterly NB (2005) Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 116(3):e439\u2013e444","journal-title":"Pediatrics"},{"issue":"6","key":"8617_CR59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/bjs.1800780613","volume":"78","author":"MD Levitt","year":"1991","unstructured":"Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK (1991) Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78(6):676\u2013678","journal-title":"Br J Surg"},{"issue":"18","key":"8617_CR60","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2165\/11638120-000000000-00000","volume":"72","author":"G Trikudanathan","year":"2012","unstructured":"Trikudanathan G, Venkatesh PG, Navaneethan U (2012) Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72(18):2333\u20132349","journal-title":"Drugs"},{"issue":"2","key":"8617_CR61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.crohns.2010.10.006","volume":"5","author":"M Polcz","year":"2011","unstructured":"Polcz M, Gu J, Florin T (2011) Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services\u2019 Adult Hospital 1998\u20132009. J Crohns Colitis 5(2):148\u2013151","journal-title":"J Crohns Colitis"},{"issue":"2","key":"8617_CR62","first-page":"88","volume":"6","author":"Y Menachem","year":"2004","unstructured":"Menachem Y, Gotsman I (2004) Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 6(2):88\u201390","journal-title":"Isr Med Assoc J"},{"issue":"5","key":"8617_CR63","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1572-0241.2006.00504.x","volume":"101","author":"GC Nguyen","year":"2006","unstructured":"Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J et al (2006) Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 101(5):1012\u20131023","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"8617_CR64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1155\/2005\/323914","volume":"19","author":"HJ Freeman","year":"2005","unstructured":"Freeman HJ (2005) Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn\u2019s disease. Can J Gastroenterol 19(10):603\u2013606","journal-title":"Can J Gastroenterol"},{"issue":"7152","key":"8617_CR65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152):427\u2013434","journal-title":"Nature"},{"issue":"6","key":"8617_CR66","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0016-5085(98)70420-2","volume":"114","author":"A Lapidus","year":"1998","unstructured":"Lapidus A, Bernell O, Hellers G, L\u00f6fberg R (1998) Clinical course of colorectal Crohn\u2019s disease: a 35-year follow-up study of 507 patients. Gastroenterology 114(6):1151\u20131160","journal-title":"Gastroenterology"},{"issue":"9","key":"8617_CR67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 350(9):876\u2013885","journal-title":"N Engl J Med"},{"issue":"1","key":"8617_CR68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0190-9622(84)80038-9","volume":"10","author":"M Lebwohl","year":"1984","unstructured":"Lebwohl M, Fleischmajer R, Janowitz H, Present D, Prioleau PG (1984) Metastatic Crohn\u2019s disease. J Am Acad Dermatol 10(1):33\u201338","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8617_CR69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11530080-000000000-00000","volume":"11","author":"EB Hawryluk","year":"2010","unstructured":"Hawryluk EB, Izikson L, English JC (2010) Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol 11(3):171\u2013181","journal-title":"Am J Clin Dermatol"},{"key":"8617_CR70","unstructured":"Guest GD, Fink RL (2000) Metastatic Crohn\u2019s disease: case report of an unusual variant and review of the literature. Dis Colon rectum 43(12):1764\u20131766"},{"issue":"4","key":"8617_CR71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00004836-199312000-00007","volume":"17","author":"AA Kafity","year":"1993","unstructured":"Kafity AA, Pellegrini AE, Fromkes JJ (1993) Metastatic Crohn\u2019s disease. A rare cutaneous manifestation. J Clin Gastroenterol 17(4):300\u2013303","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"8617_CR72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00054725-200403000-00013","volume":"10","author":"RM Hoffmann","year":"2004","unstructured":"Hoffmann RM, Kruis W (2004) Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 10(2):140\u2013147","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"8617_CR73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1590-8658(03)00080-X","volume":"35","author":"A Konrad","year":"2003","unstructured":"Konrad A, Seibold F (2003) Response of cutaneous Crohn\u2019s disease to infliximab and methotrexate. Dig Liver Dis 35(5):351\u2013356","journal-title":"Dig Liver Dis"},{"issue":"6","key":"8617_CR74","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0190-9622(88)70264-9","volume":"19","author":"JL Jorizzo","year":"1988","unstructured":"Jorizzo JL, Solomon AR, Zanolli MD, Leshin B (1988) Neutrophilic vascular reactions. J Am Acad Dermatol 19(6):983\u20131005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8617_CR75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","volume":"79","author":"ML Bennett","year":"2000","unstructured":"Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79(1):37\u201346","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"8617_CR76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","volume":"87","author":"D Farhi","year":"2008","unstructured":"Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L et al (2008) Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87(5):281\u2013293","journal-title":"Medicine (Baltimore)"},{"issue":"30","key":"8617_CR77","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","volume":"12","author":"KS Rothfuss","year":"2006","unstructured":"Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12(30):4819\u20134831","journal-title":"World J Gastroenterol"},{"issue":"9102","key":"8617_CR78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(97)10187-8","volume":"351","author":"JP Callen","year":"1998","unstructured":"Callen JP (1998) Pyoderma gangrenosum. Lancet 351(9102):581\u2013585","journal-title":"Lancet"},{"issue":"3","key":"8617_CR79","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.MIB.0000442011.60285.68","volume":"20","author":"A Weizman","year":"2014","unstructured":"Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P et al (2014) Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis 20(3):525\u2013533","journal-title":"Inflamm Bowel Dis"},{"issue":"18","key":"8617_CR80","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","volume":"347","author":"RH Weenig","year":"2002","unstructured":"Weenig RH, Davis MD, Dahl PR, Su WP (2002) Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 347(18):1412\u20131418","journal-title":"N Engl J Med"},{"issue":"9093","key":"8617_CR81","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0140-6736(05)63568-4","volume":"350","author":"RJ Powell","year":"1997","unstructured":"Powell RJ, Holbrook MR, Stevens A (1997) Pyoderma gangrenosum and its treatment. Lancet 350(9093):1720\u20131721","journal-title":"Lancet"},{"issue":"959","key":"8617_CR82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/pgmj.2004.031633","volume":"81","author":"LB Trost","year":"2005","unstructured":"Trost LB, McDonnell JK (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81(959):580\u2013585","journal-title":"Postgrad Med J"},{"issue":"3","key":"8617_CR83","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1365-2133.1999.02746.x","volume":"140","author":"S Jolles","year":"1999","unstructured":"Jolles S, Niclasse S, Benson E (1999) Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 140(3):564\u2013565","journal-title":"Br J Dermatol"},{"issue":"5","key":"8617_CR84","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/09546631003686069","volume":"22","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Trevisan V, Lazzari R, Crosti C (2011) Pyoderma gangrenosum: study of 21 patients and proposal of a \u2018clinicotherapeutic\u2019 classification. J Dermatolog Treat 22(5):254\u2013260","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"8617_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00054725-200102000-00001","volume":"7","author":"S Friedman","year":"2001","unstructured":"Friedman S, Marion JF, Scherl E, Rubin PH, Present DH (2001) Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 7(1):1\u20137","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"8617_CR86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12016-012-8351-x","volume":"45","author":"AV Marzano","year":"2013","unstructured":"Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet\u2019s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45(2):202\u2013210","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"8617_CR87","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505\u2013509","journal-title":"Gut"},{"issue":"10","key":"8617_CR88","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","volume":"58","author":"F Arg\u00fcelles-Arias","year":"2013","unstructured":"Arg\u00fcelles-Arias F, Castro-Laria L, Lobat\u00f3n T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M et al (2013) Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58(10):2949\u20132954","journal-title":"Dig Dis Sci"},{"key":"8617_CR89","doi-asserted-by":"crossref","unstructured":"Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Fr\u00f6hlich F, Seibold F et al (2017) Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 23(7):1174\u20131181","DOI":"10.1097\/MIB.0000000000001109"},{"issue":"1","key":"8617_CR90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/pde.12990","volume":"34","author":"JJ Schoch","year":"2017","unstructured":"Schoch JJ, Tolkachjov SN, Cappel JA, Gibson LE, Davis DM (2017) Pediatric pyoderma gangrenosum: a retrospective review of clinical features, etiologic associations, and treatment. Pediatr Dermatol 34(1):39\u201345","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"8617_CR91","first-page":"444","volume":"69","author":"C Becuwe","year":"1989","unstructured":"Becuwe C, Delaporte E, Colombel JF, Piette F, Cortot A, Bergoend H (1989) Sweet\u2019s syndrome associated with Crohn\u2019s disease. Acta Derm Venereol 69(5):444\u2013445","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"8617_CR92","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-4362.2003.01891.x","volume":"42","author":"PR Cohen","year":"2003","unstructured":"Cohen PR, Kurzrock R (2003) Sweet\u2019s syndrome revisited: a review of disease concepts. Int J Dermatol 42(10):761\u2013778","journal-title":"Int J Dermatol"},{"issue":"3","key":"8617_CR93","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1155\/2008\/960585","volume":"22","author":"M Ali","year":"2008","unstructured":"Ali M, Duerksen DR (2008) Ulcerative colitis and Sweet\u2019s syndrome: a case report and review of the literature. Can J Gastroenterol 22(3):296\u2013298","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"8617_CR94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-4362.1996.tb01607.x","volume":"35","author":"RL Fitzgerald","year":"1996","unstructured":"Fitzgerald RL, McBurney EI, Nesbitt LT (1996) Sweet\u2019s syndrome. Int J Dermatol 35(1):9\u201315","journal-title":"Int J Dermatol"},{"issue":"7","key":"8617_CR95","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00042737-199707000-00013","volume":"9","author":"S Travis","year":"1997","unstructured":"Travis S, Innes N, Davies MG, Daneshmend T, Hughes S (1997) Sweet\u2019s syndrome: an unusual cutaneous feature of Crohn\u2019s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 9(7):715\u2013720","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"8617_CR96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4321\/S1130-01082010000500009","volume":"102","author":"I Catal\u00e1n-Serra","year":"2010","unstructured":"Catal\u00e1n-Serra I, Mart\u00edn-Moraleda L, Navarro-L\u00f3pez L, Gil-Borr\u00e1s R, Pont-Sanju\u00e1n V, Ferrando-Marco J et al (2010) Crohn\u2019s disease and Sweet\u2019s syndrome: an uncommon association. Rev Esp Enferm Dig 102(5):331\u2013337","journal-title":"Rev Esp Enferm Dig"},{"key":"8617_CR97","doi-asserted-by":"crossref","unstructured":"von den Driesch P (1994) Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 31(4):535\u2013556","DOI":"10.1016\/S0190-9622(94)70215-2"},{"issue":"6\u20137","key":"8617_CR98","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/00365540410027184","volume":"36","author":"A Mert","year":"2004","unstructured":"Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R (2004) Erythema nodosum: an experience of 10 years. Scand J Infect Dis 36(6\u20137):424\u2013427","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"8617_CR99","first-page":"138","volume":"10","author":"JT Apgar","year":"1991","unstructured":"Apgar JT (1991) Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 10(3):138\u2013147","journal-title":"Semin Dermatol"},{"issue":"4","key":"8617_CR100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2008.05.007","volume":"26","author":"JM Mascar\u00f3","year":"2008","unstructured":"Mascar\u00f3 JM, Baselga E (2008) Erythema induratum of bazin. Dermatol Clin 26(4):439\u2013445 v","journal-title":"Dermatol Clin"},{"issue":"1","key":"8617_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","volume":"18","author":"R L\u00f6fberg","year":"2012","unstructured":"L\u00f6fberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A et al (2012) Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn\u2019s disease: results from CARE. Inflamm Bowel Dis 18(1):1\u20139","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"8617_CR102","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1365-2230.2006.02221.x","volume":"31","author":"TH Clayton","year":"2006","unstructured":"Clayton TH, Walker BP, Stables GI (2006) Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 31(6):823\u2013824","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"8617_CR103","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/ncpgasthep1099","volume":"5","author":"A Quin","year":"2008","unstructured":"Quin A, Kane S, Ulitsky O (2008) A case of fistulizing Crohn\u2019s disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol 5(5):278\u2013281","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"2","key":"8617_CR104","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00005176-200308000-00013","volume":"37","author":"S Kugathasan","year":"2003","unstructured":"Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG (2003) Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37(2):150\u2013154","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"8617_CR105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1468-3083.2006.01893.x","volume":"21","author":"N Ortego-Centeno","year":"2007","unstructured":"Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T (2007) Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 21(3):408\u2013410","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"13","key":"8617_CR106","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1097\/01.MIB.0000438356.84263.3b","volume":"19","author":"SR Vavricka","year":"2013","unstructured":"Vavricka SR, Manser CN, Hediger S, V\u00f6gelin M, Scharl M, Biedermann L et al (2013) Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 19(13):2768\u20132777","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"8617_CR107","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.1981.01650120025014","volume":"117","author":"HM VanHale","year":"1981","unstructured":"VanHale HM, Rogers RS, Doyle JA, Schroeter AL (1981) Immunofluorescence microscopic studies of recurrent aphthous stomatitis. Arch Dermatol 117(12):779\u2013781","journal-title":"Arch Dermatol"},{"issue":"1","key":"8617_CR108","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0757.2010.00350.x","volume":"55","author":"AB Berezow","year":"2011","unstructured":"Berezow AB, Darveau RP (2011) Microbial shift and periodontitis. Periodontol 2000 55(1):36\u201347","journal-title":"Periodontol 2000"},{"issue":"3","key":"8617_CR109","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0765.2011.01431.x","volume":"47","author":"RA Habashneh","year":"2012","unstructured":"Habashneh RA, Khader YS, Alhumouz MK, Jadallah K, Ajlouni Y (2012) The association between inflammatory bowel disease and periodontitis among Jordanians: a case-control study. J Periodontal Res 47(3):293\u2013298","journal-title":"J Periodontal Res"},{"issue":"6","key":"8617_CR110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","volume":"25","author":"I Kaufman","year":"2005","unstructured":"Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2005) The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease. Rheumatol Int 25(6):406\u2013410","journal-title":"Rheumatol Int"},{"issue":"9","key":"8617_CR111","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","volume":"29","author":"G Fiorino","year":"2009","unstructured":"Fiorino G, Allez M, Malesci A, Danese S (2009) Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 29(9):921\u2013927","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"8617_CR112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","volume":"13","author":"G Fiorino","year":"2014","unstructured":"Fiorino G, Danese S, Pariente B, Allez M (2014) Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents. Autoimmun Rev 13(1):15\u201319","journal-title":"Autoimmun Rev"},{"issue":"11\u201312","key":"8617_CR113","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","volume":"34","author":"G Cullen","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR (2011) Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 34(11\u201312):1318\u20131327","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"8617_CR114","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","volume":"8","author":"JF Rahier","year":"2010","unstructured":"Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E et al (2010) Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 8(12):1048\u20131055","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"8617_CR115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242\u2013251","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"8617_CR116","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102(9):3372\u20133377","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8617_CR117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","volume":"143","author":"GC Gannes de","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143(2):223\u2013231","journal-title":"Arch Dermatol"},{"issue":"5","key":"8617_CR118","doi-asserted-by":"crossref","first-page":"xiv","DOI":"10.1111\/j.0022-202X.2005.23923.x","volume":"125","author":"FO Nestle","year":"2005","unstructured":"Nestle FO, Gilliet M (2005) Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 125(5):xiv\u2013xxv","journal-title":"J Invest Dermatol"},{"issue":"11","key":"8617_CR119","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20072707","volume":"205","author":"CA Notley","year":"2008","unstructured":"Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO (2008) Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 205(11):2491\u20132497","journal-title":"J Exp Med"},{"issue":"4","key":"8617_CR120","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut 63(4):567\u2013577","journal-title":"Gut"},{"issue":"20","key":"8617_CR121","first-page":"2831","volume":"17","author":"G Andrisani","year":"2013","unstructured":"Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A et al (2013) Development of psoriasis scalp with alopecia during treatment of Crohn\u2019s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci 17(20):2831\u20132836","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"8617_CR122","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2011.1164","volume":"21","author":"S Gregoriou","year":"2011","unstructured":"Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D (2011) Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 21(1):104\u2013105","journal-title":"Eur J Dermatol"},{"key":"8617_CR123","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Van Assche G, G\u00f3mez-Ulloa D, Garc\u00eda-\u00c1lvarez L, Lara N, Black CM, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016.","DOI":"10.1016\/j.cgh.2016.06.025"},{"issue":"9","key":"8617_CR124","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","volume":"104","author":"M Barreiro-de-Acosta","year":"2012","unstructured":"Barreiro-de-Acosta M, Lorenzo A, Dom\u00ednguez-Mu\u00f1oz JE (2012) Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn\u2019s disease. Rev Esp Enferm Dig 104(9):468\u2013472","journal-title":"Rev Esp Enferm Dig"},{"issue":"5","key":"8617_CR125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","volume":"34","author":"A Rispo","year":"2005","unstructured":"Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M et al (2005) Infliximab in the treatment of extra-intestinal manifestations of Crohn\u2019s disease. Scand J Rheumatol 34(5):387\u2013391","journal-title":"Scand J Rheumatol"},{"key":"8617_CR126","doi-asserted-by":"crossref","unstructured":"Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T et al (2008) Infliximab for inflammatory bowel disease in Denmark 1999\u20132005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6(11):1212\u20131217","DOI":"10.1016\/j.cgh.2008.05.010"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-017-8617-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8617-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T19:46:35Z","timestamp":1659123995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-017-8617-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["8617"],"URL":"https:\/\/doi.org\/10.1007\/s12016-017-8617-4","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}